Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

KOSDAQ150 Rebalance in December 2023 Highlighted by Locals

KOSPI 200 and KOSDAQ 150 Rebalance Additions and Deletions Announced (December 2023)

An Early Look at the Potential KOSPI200 Rebalance Candidates in June 2024

Lunit IPO Preview: A Pioneer in AI-Based Cancer Diagnosis and Treatment Solutions

End of Mandatory Lock-Up Periods for 41 Companies in Korea in July 2023

Enchem: Block Deal Sale of 14% of Outstanding Shares

Event-Driven

<ul>
<li>On 24 August, Lunit announced a rights offering capital increase of 202 billion won. </li>
<li>Lunit's current share price is 155,700 won and its market cap is 1.9 trillion won. The expected rights offering price is 30% discount to current price.</li>
<li>We have a positive view of Lunit and its rights offering. Lunit is one of the leading companies in Korea that specializes in AI-based cancer diagnosis and treatment solutions.</li>
</ul>


On 24 August, Lunit announced a rights offering capital increase of 202 billion won. 
Lunit's current share price is 155,700 won and its market cap is 1.9 trillion won. The expected rights offering price is 30% discount to current price.
We have a positive view of Lunit and its rights offering. Lunit is one of the leading companies in Korea that specializes in AI-based cancer diagnosis and treatment solutions.


Lunit (Specializes in AI-Based Cancer Diagnosis and Treatment): Rights Offering of 202 Billion Won